Cargando…
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years h...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377320/ https://www.ncbi.nlm.nih.gov/pubmed/34422112 http://dx.doi.org/10.1177/17562864211039648 |
| _version_ | 1783740635299184640 |
|---|---|
| author | Wiendl, Heinz Gold, Ralf Berger, Thomas Derfuss, Tobias Linker, Ralf Mäurer, Mathias Aktas, Orhan Baum, Karl Berghoff, Martin Bittner, Stefan Chan, Andrew Czaplinski, Adam Deisenhammer, Florian Di Pauli, Franziska Du Pasquier, Renaud Enzinger, Christian Fertl, Elisabeth Gass, Achim Gehring, Klaus Gobbi, Claudio Goebels, Norbert Guger, Michael Haghikia, Aiden Hartung, Hans-Peter Heidenreich, Fedor Hoffmann, Olaf Kallmann, Boris Kleinschnitz, Christoph Klotz, Luisa Leussink, Verena I. Leutmezer, Fritz Limmroth, Volker Lünemann, Jan D. Lutterotti, Andreas Meuth, Sven G. Meyding-Lamadé, Uta Platten, Michael Rieckmann, Peter Schmidt, Stephan Tumani, Hayrettin Weber, Frank Weber, Martin S. Zettl, Uwe K. Ziemssen, Tjalf Zipp, Frauke |
| author_facet | Wiendl, Heinz Gold, Ralf Berger, Thomas Derfuss, Tobias Linker, Ralf Mäurer, Mathias Aktas, Orhan Baum, Karl Berghoff, Martin Bittner, Stefan Chan, Andrew Czaplinski, Adam Deisenhammer, Florian Di Pauli, Franziska Du Pasquier, Renaud Enzinger, Christian Fertl, Elisabeth Gass, Achim Gehring, Klaus Gobbi, Claudio Goebels, Norbert Guger, Michael Haghikia, Aiden Hartung, Hans-Peter Heidenreich, Fedor Hoffmann, Olaf Kallmann, Boris Kleinschnitz, Christoph Klotz, Luisa Leussink, Verena I. Leutmezer, Fritz Limmroth, Volker Lünemann, Jan D. Lutterotti, Andreas Meuth, Sven G. Meyding-Lamadé, Uta Platten, Michael Rieckmann, Peter Schmidt, Stephan Tumani, Hayrettin Weber, Frank Weber, Martin S. Zettl, Uwe K. Ziemssen, Tjalf Zipp, Frauke |
| author_sort | Wiendl, Heinz |
| collection | PubMed |
| description | Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland). |
| format | Online Article Text |
| id | pubmed-8377320 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83773202021-08-21 Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) Wiendl, Heinz Gold, Ralf Berger, Thomas Derfuss, Tobias Linker, Ralf Mäurer, Mathias Aktas, Orhan Baum, Karl Berghoff, Martin Bittner, Stefan Chan, Andrew Czaplinski, Adam Deisenhammer, Florian Di Pauli, Franziska Du Pasquier, Renaud Enzinger, Christian Fertl, Elisabeth Gass, Achim Gehring, Klaus Gobbi, Claudio Goebels, Norbert Guger, Michael Haghikia, Aiden Hartung, Hans-Peter Heidenreich, Fedor Hoffmann, Olaf Kallmann, Boris Kleinschnitz, Christoph Klotz, Luisa Leussink, Verena I. Leutmezer, Fritz Limmroth, Volker Lünemann, Jan D. Lutterotti, Andreas Meuth, Sven G. Meyding-Lamadé, Uta Platten, Michael Rieckmann, Peter Schmidt, Stephan Tumani, Hayrettin Weber, Frank Weber, Martin S. Zettl, Uwe K. Ziemssen, Tjalf Zipp, Frauke Ther Adv Neurol Disord Review Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland). SAGE Publications 2021-08-18 /pmc/articles/PMC8377320/ /pubmed/34422112 http://dx.doi.org/10.1177/17562864211039648 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Review Wiendl, Heinz Gold, Ralf Berger, Thomas Derfuss, Tobias Linker, Ralf Mäurer, Mathias Aktas, Orhan Baum, Karl Berghoff, Martin Bittner, Stefan Chan, Andrew Czaplinski, Adam Deisenhammer, Florian Di Pauli, Franziska Du Pasquier, Renaud Enzinger, Christian Fertl, Elisabeth Gass, Achim Gehring, Klaus Gobbi, Claudio Goebels, Norbert Guger, Michael Haghikia, Aiden Hartung, Hans-Peter Heidenreich, Fedor Hoffmann, Olaf Kallmann, Boris Kleinschnitz, Christoph Klotz, Luisa Leussink, Verena I. Leutmezer, Fritz Limmroth, Volker Lünemann, Jan D. Lutterotti, Andreas Meuth, Sven G. Meyding-Lamadé, Uta Platten, Michael Rieckmann, Peter Schmidt, Stephan Tumani, Hayrettin Weber, Frank Weber, Martin S. Zettl, Uwe K. Ziemssen, Tjalf Zipp, Frauke Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) |
| title | Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) |
| title_full | Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) |
| title_fullStr | Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) |
| title_full_unstemmed | Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) |
| title_short | Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) |
| title_sort | multiple sclerosis therapy consensus group (mstcg): position statement on disease-modifying therapies for multiple sclerosis (white paper) |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377320/ https://www.ncbi.nlm.nih.gov/pubmed/34422112 http://dx.doi.org/10.1177/17562864211039648 |
| work_keys_str_mv | AT wiendlheinz multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT goldralf multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT bergerthomas multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT derfusstobias multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT linkerralf multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT maurermathias multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT aktasorhan multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT baumkarl multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT berghoffmartin multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT bittnerstefan multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT chanandrew multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT czaplinskiadam multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT deisenhammerflorian multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT dipaulifranziska multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT dupasquierrenaud multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT enzingerchristian multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT fertlelisabeth multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT gassachim multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT gehringklaus multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT gobbiclaudio multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT goebelsnorbert multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT gugermichael multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT haghikiaaiden multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT hartunghanspeter multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT heidenreichfedor multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT hoffmannolaf multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT kallmannboris multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT kleinschnitzchristoph multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT klotzluisa multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT leussinkverenai multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT leutmezerfritz multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT limmrothvolker multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT lunemannjand multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT lutterottiandreas multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT meuthsveng multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT meydinglamadeuta multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT plattenmichael multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT rieckmannpeter multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT schmidtstephan multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT tumanihayrettin multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT weberfrank multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT webermartins multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT zettluwek multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT ziemssentjalf multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT zippfrauke multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper AT multiplesclerosistherapyconsensusgroupmstcgpositionstatementondiseasemodifyingtherapiesformultiplesclerosiswhitepaper |